ESLA - estrellabio.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The development of leukemia treatment methods remains independent of economic cycles, as evidenced by the market price fluctuations of Estrella Immunopharma (ESLA) shares on GURU.Markets with the indicator 0.00. Estrella Immunopharma (ESLA) is implementing automated molecule screening and software robots for data processing. However, global conflicts and trade restrictions are hindering the cross-border logistics of biomaterials, slowing down international certification and the execution of clinical trials.

ESLA Estrella Bio: Company Value to EBITDA in the range 11/23/2025 - 11/14/2026

estrellabio.com - analytical breakdowns and key metrics (ESLA)

- current price and projected stock value:

Stock Price Estrella Bio|ESLA - Price Target Chart

- market capitalization statistics:

Market Value Estrella Immunopharma Corp|ESLA - Total Company Value

- book value of equity indicators:

Net Assets per Single Share Estrella Immunopharma|ESLA - Total Stockholders' Equity|Market Value to Book Value Ratio estrellabio.com|ESLA - Company Assets

- business debt structure and liquidity details:

Total Debt to Capital Estrella Immunopharma|ESLA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Estrella Immunopharma, Inc.|ESLA - Company Cumulative Debt|Debt to Book Capitalization Ratio Estrella Immunopharma Corp|ESLA - Long-Term Debt Volume|Company Current Liabilities Estrella Immunopharma|Quick Liquidity estrellabio.com

- business earnings and investment ratios data:

ESLA - Final Profit|Projected Future Earnings Estrella Immunopharma|ESLA - Market Cap to Earnings|Future Price to Earnings Estrella Immunopharma|ESLA - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Estrella Immunopharma Corp|ESLA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Estrella Immunopharma|ESLA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months estrellabio.com|ESLA - Earnings per share increase in current year|Earnings growth forecast for next year Estrella Immunopharma

- revenue and sales details:

ESLA - Company Gross Revenue|Company Projected Revenue Estrella Bio|ESLA - Market Cap to Revenue|Price-to-Projected Revenue Ratio Estrella Immunopharma Corp

Initial company analysis:ESLA (Estrella Bio)

The protected R&D perimeter of the ARTEMIS platform creates high barriers to entry for competitors in the cellular oncology therapy sector. By analyzing changes in the EV/EBITDA multiple, investors assess the total value of Estrella Immunopharma (ESLA) relative to operating profit, which enables the identification of market shocks and the determination of the asset's fundamental floor, accounting for the impact of debt load and tax liabilities on the final enterprise value.

Analysis of competing companies

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kura Oncology (KURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ADC Therapeutics S.A. (ADCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics, Inc.|Company Value to EBITDA Vor Bio Inc. VOR|EV/EBITDA Multiple NKTX|coeptistx.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATNM (Actinium Pharmaceuticals, Inc.)|CASI Pharmaceuticals Inc. (CASI) - Company Value to EBITDA|MRKR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio IN8bio Inc INAB|ERNA (eternatx.com) - Enterprise Value to EBITDA Ratio|GTBP: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptose Biosciences Inc|BPTH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MEIP|VINC - Company Value to EBITDA